Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay ... that sought to include the results of the phase 3 GATHER2 trial and improve the drug's competitive ...

Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Major advances in understanding both the clinical and molecular features, as well as the underlying pathophysiology, have culminated in many completed, ongoing and planned human clinical trials of ...

QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

Advt Sported by AI, the research has created the most detailed maps of the retina ever produced. WEHI researchers have used these maps to link retinal thinning to a range of diseases as well as ...